A slight majority of more than 7,000 residents in the Indianapolis Public Schools district are dissatisfied with the school system, according to surveys conducted in late summer by a coalition of community groups, including IPS itself.
The amount of venture capital invested in medical-device and equipment companies nationally has declined each quarter this year, reaching levels not seen since 2004, according to data released Oct. 19 by the National Venture Capital Association and PricewaterhouseCoopers.
Eli Lilly and Co. suffered a tough week on the stock market, in part because of a disturbing bit of news buried in its third-quarter earnings report: Lilly’s insulin sales are down.
ITT Educational Services Inc. will not close any of its campuses in response to plummeting student enrollment, but it likely will spend more of its own money to give scholarships to students, company officials said Thursday.
The Warsaw-based maker of orthopedic implants beat analysts’ estimates with its third-quarter earnings, but lowered its full-year forecast.
Shareholders of Amerigroup Corp. overwhelming approved the Virginia company’s sale for $4.9 billion to Indianapolis-based health insurer WellPoint Inc. in a vote on Tuesday. The vote clears the way for the acquisition to close before the end of the year.
Strong demand from farmers boosted sales by 8 percent at Dow AgroSciences LLC in the third quarter, but continued investments in new technologies slashed profits by 16 percent.
Third-quarter earnings at Eli Lilly and Co. fell short of analysts’ expectations, and the Indianapolis-based drugmaker reduced its profit forecast by 4 cents per share for the remainder of the year.
Eli Lilly CEO John Lechleiter on Tuesday called for creation of a “world-class” research institute in Indianapolis to bring together scientists from universities and corporations to develop new medical therapies and companies.
Eli Lilly and Co. is continuing a string of positive yet incomplete clinical trial results, giving it a boost among investors.
Roche officials said last week that price competition and lower reimbursement rates are forcing it to make an unspecified number of cuts in its U.S. sales force and at its research and development hubs in Indianapolis and Germany.
Eli Lilly and Co. said dulaglutide lowered blood sugar better than three existing diabetes drugs in three Phase 3 clinical trials. Analysts expect the drug to hit the market in 2014 or 2015 and become a blockbuster.
Charles A. Tindley Accelerated School, which currently has two locations, will use a $1.6 million grant from the Charter School Growth Fund to open five more schools over the next three years.
Indianapolis-based medical-device maker Catheter Research Inc. will receive a new kind of sterilization machine in December that it hopes will reduce costs and wait times for medical-device companies in the Midwest—including itself.
Eli Lilly and Co. has apparently made major medical history by being the first to develop a drug that alters the course of Alzheimer’s disease. But whether Lilly can be the first to make major money from a disease-altering Alzheimer’s drug is still in doubt.
Indianapolis-based ExactTarget Inc., which grew up as an e-mail blasting company focused on consumers, is trying to entrench itself as a one-stop shop for smartly interacting with all manner of customers.
Universities are the hubs of the world’s knowledge economy, but they typically aren’t the smartest business operators in the world. Brad Wheeler, chief information officer at Indiana University in Bloomington, is working to change that.
Both Marian and Teach for America say not enough people are prepared to lead schools in Indianapolis and around the state in areas of low income, high crime and broken homes.
Eli Lilly and Co.’s Alzheimer’s drug slowed cognitive decline 34 percent in patients with mild forms of the disease, according to an analysis of Lilly’s clinical trial data released Monday. Lilly’s share price jumped more than 5 percent on the news.
New health insurance coverage created by the 2010 health reform law will attract a lower-income, less-educated and more diverse set of customers than the insurance markets that exist today, according to a new analysis by PricewaterhouseCoopers. And that could create challenges for doctors and hospitals trying to care for those patients.
